ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Permissions
Right arrowRequest Permissions
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Faurschou, P
Right arrow Articles by Jacques, L
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Faurschou, P
Right arrow Articles by Jacques, L
Eur Respir J 1996; 9: 1885-1890
Copyright © ERS Journals Ltd 1996


Clinical Trial

Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids. European Respiratory Study Group

P Faurschou, I Steffensen, and L Jacques

The aim of this study was to assess the efficacy and safety of inhaled salmeterol 100 micrograms b.d. (SM) versus inhaled salbutamol 400 micrograms q.d.s. (SB), both via the Diskhaler, when added to concurrent treatment, in asthmatic patients who were not controlled on high doses of inhaled steroids (> or = 1,500 micrograms beclomethasone dipropionate (BDP) or equivalent daily). This was a multicentre, parallel group, double-blind study in which 190 patients with a forced expiratory volume in one second (FEV1) or peak expiratory flow rate (PEFR) of 30-75% predicted and 15% reversibility to inhaled bronchodilator were randomized to treatment for 6 weeks. In the SM group, morning PEFR increased from 281 to 315 L-min-1 during treatment and in the SB group from 311 to 315 L.min-1 (p < 0.001). The SM group showed significantly better reduction in diurnal variation, from 39 to 22 L.min-1 during treatment, than the SB group (34 to 37 L.min-1) (p < 0.001). There was a significantly greater improvement in FEV1 in the SM group (from 1.63 to 1.85 L) than in the SB group (from 1.79 to 1.84 L). The SM group had significantly more symptom-free nights than the SB group (p < 0.001), and also more "rescue-free" nights (p = 0.04). The adverse event profile was similar in both groups. This study indicates that in asthmatic patients, not controlled on high-dose inhaled steroids, inhaled salmeterol 100 micrograms b.d. significantly improves lung function and reduces asthma symptoms.


This article has been cited by other articles:


Home page
ChestHome page
J. A. Nightingale, D. F. Rogers, and P. J. Barnes
Comparison of the Effects of Salmeterol and Formoterol in Patients With Severe Asthma*
Chest, May 1, 2002; 121(5): 1401 - 1406.
[Abstract] [Full Text] [PDF]


Home page
Fam PractHome page
M. Eccles, N. Rousseau, B. Higgins, and L. Thomas
Evidence-based guideline on the primary care management of asthma
Fam. Pract., April 1, 2001; 18(2): 223 - 229.
[Full Text] [PDF]


Home page
ChestHome page
J. I. Peters, D. C. Shelledy, A. P. Jones Jr., R. W. Lawson, C. P. Davis, and T. S. LeGrand
A Randomized, Placebo-Controlled Study To Evaluate the Role of Salmeterol in the In-Hospital Management of Asthma
Chest, August 1, 2000; 118(2): 313 - 320.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
J. W. Georgitis
The 1997 Asthma Management Guidelines and Therapeutic Issues Relating to the Treatment of Asthma
Chest, January 1, 1999; 115(1): 210 - 217.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the European Respiratory Society.